Development Research Program

发展研究计划

基本信息

批准号：
10708093
负责人：
John R. Hawse
金额：
$ 28.35万
依托单位：
MAYO CLINIC ROCHESTER
依托单位国家：
美国
项目类别：
财政年份：
2005
资助国家：
美国
起止时间：
2005-07-01 至 2027-08-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10708093
关键词：
Achievement Advisory Committees Advocacy American Association of Cancer Research American Cancer Society Applications Grants Award Breast Breast Cancer Patient Cancer Center Clinic Clinical Clinical Research Collaborations Data Decision Making Detection Development Diagnosis Direct Costs Disabled Persons Disease Ensure Ethnic Population Evaluation Extramural Activities Foundations Funding Future Generations Goals Grant Human Resources Incidence Institution Journals Laboratory Study Leadership Letters Manuscripts Mayo Clinic Cancer Center Mentors Minnesota Minority Monitor Peer Review Performance Pilot Projects Policies Population Study Prevention Procedures Process Productivity Program Research Project Grants Progress Reports Publications Publishing Qualifying Quality of life Regenerative Medicine Research Research Personnel Research Project Grants Selection Criteria Site Visit Testing Translating Translational Research Universities Utilization Review Veterans Woman anticancer research career clinical center diversity and inclusion expectation experience innovation interdisciplinary collaboration malignant breast neoplasm meetings member mortality originality programs racial population recruit research and development success symposium translational potential translational study

项目摘要

PROJECT SUMMARY The goal of the DRP is to support innovative and scientifically meritorious research projects that can be translated into clinically important applications impacting diagnosis and management of breast cancer to decrease the burden and mortality from this disease. The DRP will: 1) encourage and solicit innovative translational laboratory, population, and clinical study proposals; 2) encourage and support interdisciplinary collaboration in translational research in breast cancer; and 3) generate new hypotheses that can be tested in larger-scale research projects. This support will expand the research portfolio of the SPORE. The Developmental Research Program will provide $50,000 direct costs for one year ($25,000 from SPORE funds and $25,000 from Mayo Clinic Cancer Center) to each of six projects. Additionally, the DRP will provide an additional $25,000 direct costs/year for each of the 5 years to support one project led by an investigator from an underrepresented racial and ethnic group. This will be matched with an additional 25K from the Mayo Clinic Cancer Center or our collaborating institutions, University of Minnesota Masonic Cancer Center and Emory Cancer Center. In all cases, there will be the expectation of a second year of support contingent on sufficient progress. A process has been established involving a call for applications and a formal peer review utilizing the expertise of the Internal Scientific Advisory Committee and other experienced investigators. Criteria for selection of projects for funding are based upon scientific merit, originality, qualifications of the applicant, and translational potential. It is expected that support of developmental research projects will result in generation of data that will serve as the basis for additional SPORE-sponsored projects or support through peer-reviewed external grant support. The three main metrics for productivity of the DRP are advancement of DRP projects to a full Project in the SPORE, acquisition of extramural funding, and publications by the project awardees. There have been 41 DRP awardees with four awards being made on September 1, 2020. Six of the eleven SPORE projects in the current grant (two), previous grant (two), and renewal (two) have a Co-Leader who was a DRP awardee. The 36 DRP awardees (before September 1, 2020) have obtained 17 R01s, nine Foundation grants, three Komen grants, one State of Minnesota grant, one R21, one American Association for Cancer Research grant, one American Cancer Society grant, one Eagle’s grant, one Regenerative Medicine Minnesota grant, and three Breast SPORE Career Enhancement Awards, in addition to the five awardees who have advanced to Co-Leadership of a full project in the Breast SPORE. These 36 awardees have published 115 manuscripts related to their DRP projects in peer-reviewed journals. The DRP has been highly successful in identifying cadre of investigators that has expanded and enriched the scientific portfolio of the SPORE and provided a mechanism for development of Co-Leaders in full Projects.

项目概要 DRP 的目标是支持可转化的创新且具有科学价值的研究项目进入影响乳腺癌诊断和治疗的临床重要应用，以减少 DRP 将：1) 鼓励和征求创新转化实验室，人群和临床研究提案；2）鼓励和支持转化方面的跨学科合作；乳腺癌研究；3）产生可以在更大规模的研究项目中进行测试的新假设。这项支持将扩大 SPORE 发展研究计划的研究范围。一年 50,000 美元的直接费用（25,000 美元来自 SPORE 基金，25,000 美元来自 Mayo Clinic 癌症中心）此外，DRP 将为这 5 个项目中的每一个每年提供 25,000 美元的额外直接费用。数年的时间来支持一个由代表性不足的种族和族裔群体的调查员领导的项目。与 Mayo Clinic 癌症中心或我们的合作机构提供的额外 25K 相匹配，在所有情况下，都会有明尼苏达大学共济会癌症中心和埃默里癌症中心。预计第二年的支持取决于是否取得了足够的进展。包括利用内部科学咨询的专业知识进行申请征集和正式同行评审委员会和其他经验丰富的研究人员选择资助项目的标准是基于的。科学价值、原创性、申请人的资格和转化潜力。的发展研究项目将产生数据，这些数据将作为其他研究的基础 SPORE 赞助的项目或通过同行评审的外部赠款支持提供的支持的三个主要指标。 DRP 的生产力包括将 DRP 项目推进为 SPORE 中的完整项目、收购外部资源项目获奖者的资助和出版物共有 41 名 DRP 获奖者，其中有 4 个奖项。于 2020 年 9 月 1 日做出。当前拨款（两个）、先前拨款（两个）的 11 个 SPORE 项目中的 6 个，和更新 (2) 有一位联合领导者是 DRP 获奖者 36 名 DRP 获奖者（9 月 1 日之前）。 2020）已获得 17 项 R01、9 项基金会拨款、3 项 Komen 拨款、1 项明尼苏达州拨款、1 项 R21、一项美国癌症研究协会拨款、一项美国癌症协会拨款、一项 Eagle’s 拨款补助金、一项明尼苏达州再生医学补助金和三项乳腺 SPORE 职业发展奖，另外还有五位获奖者，他们已晋升为乳房孢子 (Breast SPORE) 整个项目的共同领导者。 36 名获奖者在同行评审期刊 The DRP 上发表了 115 篇与其 DRP 项目相关的手稿。在确定研究人员骨干方面取得了巨大成功，扩大和丰富了科学知识 SPORE 的投资组合，并提供了在整个项目中共同领导者发展的机制。